BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29206234)

  • 1. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
    PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy.
    Jiang G; Hu Q; Wang H; Ding W; Zhang N; Wu Y; Zhou Q; Sun C; Xia G; Ding Q; Na R; Xu K
    Ann Clin Lab Sci; 2018 Jan; 48(1):18-28. PubMed ID: 29530992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
    Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
    Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J
    Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.
    Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A
    BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer.
    Whiteland H; Spencer-Harty S; Thomas DH; Davies C; Morgan C; Kynaston H; Bose P; Fenn N; Lewis PD; Bodger O; Jenkins S; Doak SH
    Exp Mol Pathol; 2013 Oct; 95(2):220-6. PubMed ID: 23933194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamin A/C might be involved in the EMT signalling pathway.
    Zuo L; Zhao H; Yang R; Wang L; Ma H; Xu X; Zhou P; Kong L
    Gene; 2018 Jul; 663():51-64. PubMed ID: 29665450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
    Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
    Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
    Johnston WL; Catton CN; Swallow CJ
    BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
    Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
    Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
    Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma.
    Lai CY; Chen CM; Hsu WH; Hsieh YH; Liu CJ
    Int J Med Sci; 2017; 14(12):1263-1267. PubMed ID: 29104483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
    Pistore C; Giannoni E; Colangelo T; Rizzo F; Magnani E; Muccillo L; Giurato G; Mancini M; Rizzo S; Riccardi M; Sahnane N; Del Vescovo V; Kishore K; Mandruzzato M; Macchi F; Pelizzola M; Denti MA; Furlan D; Weisz A; Colantuoni V; Chiarugi P; Bonapace IM
    Oncogene; 2017 Oct; 36(40):5551-5566. PubMed ID: 28581528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
    Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
    Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.